{"altmetric_id":23631420,"counts":{"readers":{"mendeley":1,"citeulike":0,"connotea":0},"total":{"posts_count":1},"reddit":{"unique_users_count":1,"unique_users":["montaukwhaler"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4fe3cf058f610003039","authors":["Reck, Martin","Paz-Ares, Luis","Bidoli, Paolo","Cappuzzo, Federico","Dakhil, Shaker","Moro-Sibilot, Denis","Borghaei, Hossein","Johnson, Melissa","Jotte, Robert","Pennell, Nathan A.","Shepherd, Frances A.","Tsao, Anne","Thomas, Michael","Carter, Gebra Cuyun","Chan-Diehl, Faye","Alexandris, Ekaterine","Lee, Pablo","Zimmermann, Annamaria","Sashegyi, Andreas","P\u00e9rol, Maurice"],"doi":"10.1016\/j.lungcan.2017.07.038","first_seen_on":"2017-08-11T18:20:36+00:00","issns":["0169-5002","01695002"],"journal":"Lung Cancer (01695002)","last_mentioned_on":1502427162,"links":["http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0169500217304373"],"pubdate":"2017-08-01T00:00:00+00:00","publisher":"Elsevier BV","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"},{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"title":"Outcomes in patients with aggressive or refractory disease from REVEL, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/outcomes-patients-aggressive-refractory-disease-revel-randomized-phase-iii-study-docetaxel-ramucirum"},"altmetric_score":{"score":0.25,"score_history":{"1y":0.25,"6m":0.25,"3m":0.25,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":8355069,"mean":7.046560105308,"rank":7222517,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":8355069,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":178795,"mean":12.461464020045,"rank":146037,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":178795,"percentile":1},"this_journal":{"total_number_of_other_articles":873,"mean":8.5647385321101,"rank":715,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":873,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":27,"mean":49.423076923077,"rank":21,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":27,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":{"Other":1},"by_discipline":{"Agricultural and Biological Sciences":1}}}},"posts":{"reddit":[{"title":"Outcomes in patients with aggressive or refractory disease from REVEL, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","url":"http:\/\/www.reddit.com\/r\/nsclc\/comments\/6syz2m\/outcomes_in_patients_with_aggressive_or\/","license":"public","citation_ids":[23631420],"posted_on":"2017-08-11T04:52:42+00:00","author":{"name":"montaukwhaler","url":"http:\/\/www.reddit.com\/r\/nsclc","id_on_source":"nsclc","followers":1,"subreddit":"non small cell lung cancer"}}]}}